Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2015 | Pages:
355 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Esophageal Cancer - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Esophageal Cancer - Pipeline Review, H2 2015', provides an overview of the Esophageal Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Esophageal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Esophageal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Esophageal Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Esophageal Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents
2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Esophageal Cancer Overview 10 Therapeutics Development 11 Pipeline Products for Esophageal Cancer - Overview 11 Pipeline Products for Esophageal Cancer - Comparative Analysis 12 Esophageal Cancer - Therapeutics under Development by Companies 13 Esophageal Cancer - Therapeutics under Investigation by Universities/Institutes 17 Esophageal Cancer - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Esophageal Cancer - Products under Development by Companies 21 Esophageal Cancer - Products under Investigation by Universities/Institutes 25 Esophageal Cancer - Companies Involved in Therapeutics Development 26 Adaptimmune Limited 26 Advantagene, Inc. 27 Advaxis, Inc. 28 Amgen Inc. 29 ArQule, Inc. 30 Array BioPharma Inc. 31 Aslan Pharmaceuticals Pte. Ltd. 32 AstraZeneca Plc 33 ATLAB Pharma SAS 34 AVEO Pharmaceuticals, Inc. 35 Bayer AG 36 Boehringer Ingelheim GmbH 37 Celgene Corporation 38 Celldex Therapeutics, Inc. 39 Cellectar Biosciences, Inc. 40 Cerulean Pharma, Inc. 41 Cyclacel Pharmaceuticals, Inc. 42 Daiichi Sankyo Company, Limited 43 Genmab A/S 44 Glycotope GmbH 45 Hutchison MediPharma Limited 46 Ignyta, Inc. 47 ImmunoFrontier, Inc. 48 ImmunoGen, Inc. 49 Immunomedics, Inc. 50 Johnson & Johnson 51 Karyopharm Therapeutics, Inc. 52 MacroGenics, Inc. 53 Mebiopharm Co., Ltd. 54 MedImmune, LLC 55 Novartis AG 56 Omeros Corporation 57 Omnitura Therapeutics Inc. 58 Oncolys BioPharma Inc. 59 Ono Pharmaceutical Co., Ltd. 60 Pfizer Inc. 61 Precision Biologics, Inc. 62 Proteo, Inc. 63 Puma Biotechnology, Inc. 64 Shionogi & Co., Ltd. 65 Spectrum Pharmaceuticals, Inc. 66 Symphogen A/S 67 Synta Pharmaceuticals Corp. 68 Transgene Biotek Limited 69 VioQuest Pharmaceuticals, Inc. 70 Virocan Therapeutics Private Limited 71 Zhejiang BetaPharma Co., Ltd. 72 Esophageal Cancer - Therapeutics Assessment 73 Assessment by Monotherapy Products 73 Assessment by Target 74 Assessment by Mechanism of Action 78 Assessment by Route of Administration 81 Assessment by Molecule Type 83 Drug Profiles 85 1-BB1 - Drug Profile 85 ADXS-HER2 - Drug Profile 87 afatinib dimaleate - Drug Profile 88 alpelisib - Drug Profile 92 AMG-337 - Drug Profile 94 ATL-101 - Drug Profile 95 binimetinib - Drug Profile 97 CDX-1401 - Drug Profile 102 Cell Therapy 1 for Oncology - Drug Profile 104 Cell Therapy to Target NY-ESO-1 for Oncology - Drug Profile 105 Cell Therapy to Target NY-ESO-1 for Oncology - Drug Profile 107 cetuximab biobetter - Drug Profile 108 CRLX-101 - Drug Profile 109 CYC-140 - Drug Profile 112 dacomitinib - Drug Profile 113 DKN-01 - Drug Profile 116 durvalumab - Drug Profile 118 elgemtumab - Drug Profile 121 ficlatuzumab - Drug Profile 123 futuximab - Drug Profile 125 ganetespib - Drug Profile 127 gedatolisib - Drug Profile 131 gefitinib - Drug Profile 133 Gene Therapy for Esophageal Cancer - Drug Profile 138 Gene Therapy to Activate p53 for Oncology - Drug Profile 139 HMPL-309 - Drug Profile 140 HuMax-TF-ADC - Drug Profile 141 I131-CLR1404 - Drug Profile 143 icotinib hydrochloride - Drug Profile 145 IMF-001 - Drug Profile 147 IMGN-289 - Drug Profile 148 JNJ-42756493 - Drug Profile 149 margetuximab - Drug Profile 151 MBP-426 - Drug Profile 153 MMD-37K - Drug Profile 155 MVXONCO-1 - Drug Profile 156 NEO-201 - Drug Profile 157 neratinib - Drug Profile 158 nimotuzumab - Drug Profile 163 nintedanib - Drug Profile 167 nivolumab - Drug Profile 172 OBP-301 - Drug Profile 179 OMN-54 - Drug Profile 180 paclitaxel albumin bound - Drug Profile 182 panitumumab - Drug Profile 186 pasireotide LAR - Drug Profile 189 patritumab - Drug Profile 191 PCA-062 - Drug Profile 193 pralatrexate - Drug Profile 194 PTVICN-001 - Drug Profile 197 rAAV-VICN003 - Drug Profile 198 RXDX-106 - Drug Profile 199 S-588410 - Drug Profile 201 sacituzumab govitecan - Drug Profile 202 selinexor - Drug Profile 204 Small Molecule to Antagonize GPR39 for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes - Drug Profile 210 Small Molecule to Target LGR5 for Esophageal Adenocarcinoma - Drug Profile 211 Small Molecules to Inhibit Histone Demethylase for Esophageal Cancer - Drug Profile 212 SMYD-2BAY02 - Drug Profile 213 TBL-0805E - Drug Profile 214 tiprelestat - Drug Profile 215 tivantinib - Drug Profile 218 triciribine phosphate - Drug Profile 220 Vaccine for Esophageal Cancer - Drug Profile 223 Vaccine for Esophageal Cancer and Colorectal Cancer - Drug Profile 224 varlitinib - Drug Profile 225 Esophageal Cancer - Recent Pipeline Updates 228 Esophageal Cancer - Dormant Projects 336 Esophageal Cancer - Discontinued Products 340 Esophageal Cancer - Product Development Milestones 341 Featured News & Press Releases 341 Appendix 349 Methodology 349 Coverage 349 Secondary Research 349 Primary Research 349 Expert Panel Validation 349 Contact Us 349 Disclaimer 350
List of Tables
Number of Products under Development for Esophageal Cancer, H2 2015 16 Number of Products under Development for Esophageal Cancer - Comparative Analysis, H2 2015 17 Number of Products under Development by Companies, H2 2015 19 Number of Products under Development by Companies, H2 2015 (Contd..1) 20 Number of Products under Development by Companies, H2 2015 (Contd..2) 21 Number of Products under Investigation by Universities/Institutes, H2 2015 22 Comparative Analysis by Late Stage Development, H2 2015 23 Comparative Analysis by Clinical Stage Development, H2 2015 24 Comparative Analysis by Early Stage Development, H2 2015 25 Products under Development by Companies, H2 2015 26 Products under Development by Companies, H2 2015 (Contd..1) 27 Products under Development by Companies, H2 2015 (Contd..2) 28 Products under Development by Companies, H2 2015 (Contd..3) 29 Products under Investigation by Universities/Institutes, H2 2015 30 Esophageal Cancer - Pipeline by Adaptimmune Limited, H2 2015 31 Esophageal Cancer - Pipeline by Advantagene, Inc., H2 2015 32 Esophageal Cancer - Pipeline by Advaxis, Inc., H2 2015 33 Esophageal Cancer - Pipeline by Amgen Inc., H2 2015 34 Esophageal Cancer - Pipeline by ArQule, Inc., H2 2015 35 Esophageal Cancer - Pipeline by Array BioPharma Inc., H2 2015 36 Esophageal Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2015 37 Esophageal Cancer - Pipeline by AstraZeneca Plc, H2 2015 38 Esophageal Cancer - Pipeline by ATLAB Pharma SAS, H2 2015 39 Esophageal Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015 40 Esophageal Cancer - Pipeline by Bayer AG, H2 2015 41 Esophageal Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2015 42 Esophageal Cancer - Pipeline by Celgene Corporation, H2 2015 43 Esophageal Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2015 44 Esophageal Cancer - Pipeline by Cellectar Biosciences, Inc., H2 2015 45 Esophageal Cancer - Pipeline by Cerulean Pharma, Inc., H2 2015 46 Esophageal Cancer - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2015 47 Esophageal Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 48 Esophageal Cancer - Pipeline by Genmab A/S, H2 2015 49 Esophageal Cancer - Pipeline by Glycotope GmbH, H2 2015 50 Esophageal Cancer - Pipeline by Hutchison MediPharma Limited, H2 2015 51 Esophageal Cancer - Pipeline by Ignyta, Inc., H2 2015 52 Esophageal Cancer - Pipeline by ImmunoFrontier, Inc., H2 2015 53 Esophageal Cancer - Pipeline by ImmunoGen, Inc., H2 2015 54 Esophageal Cancer - Pipeline by Immunomedics, Inc., H2 2015 55 Esophageal Cancer - Pipeline by Johnson & Johnson, H2 2015 56 Esophageal Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 57 Esophageal Cancer - Pipeline by MacroGenics, Inc., H2 2015 58 Esophageal Cancer - Pipeline by Mebiopharm Co., Ltd., H2 2015 59 Esophageal Cancer - Pipeline by MedImmune, LLC, H2 2015 60 Esophageal Cancer - Pipeline by Novartis AG, H2 2015 61 Esophageal Cancer - Pipeline by Omeros Corporation, H2 2015 62 Esophageal Cancer - Pipeline by Omnitura Therapeutics Inc., H2 2015 63 Esophageal Cancer - Pipeline by Oncolys BioPharma Inc., H2 2015 64 Esophageal Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 65 Esophageal Cancer - Pipeline by Pfizer Inc., H2 2015 66 Esophageal Cancer - Pipeline by Precision Biologics, Inc., H2 2015 67 Esophageal Cancer - Pipeline by Proteo, Inc., H2 2015 68 Esophageal Cancer - Pipeline by Puma Biotechnology, Inc., H2 2015 69 Esophageal Cancer - Pipeline by Shionogi & Co., Ltd., H2 2015 70 Esophageal Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015 71 Esophageal Cancer - Pipeline by Symphogen A/S, H2 2015 72 Esophageal Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2015 73 Esophageal Cancer - Pipeline by Transgene Biotek Limited, H2 2015 74 Esophageal Cancer - Pipeline by VioQuest Pharmaceuticals, Inc., H2 2015 75 Esophageal Cancer - Pipeline by Virocan Therapeutics Private Limited, H2 2015 76 Esophageal Cancer - Pipeline by Zhejiang BetaPharma Co., Ltd., H2 2015 77 Assessment by Monotherapy Products, H2 2015 78 Number of Products by Stage and Target, H2 2015 80 Number of Products by Stage and Mechanism of Action, H2 2015 84 Number of Products by Stage and Route of Administration, H2 2015 87 Number of Products by Stage and Molecule Type, H2 2015 89 Esophageal Cancer Therapeutics - Recent Pipeline Updates, H2 2015 233 Esophageal Cancer - Dormant Projects, H2 2015 341 Esophageal Cancer - Dormant Projects (Contd..1), H2 2015 342 Esophageal Cancer - Dormant Projects (Contd..2), H2 2015 343 Esophageal Cancer - Dormant Projects (Contd..3), H2 2015 344 Esophageal Cancer - Discontinued Products, H2 2015 345
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
